Eli Lilly and Company $LLY Shares Sold by Private Advisory Group LLC

Private Advisory Group LLC cut its holdings in Eli Lilly and Company (NYSE:LLY) by 11.1% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,942 shares of the company’s stock after selling 1,990 shares during the period. Eli Lilly and Company comprises about 1.0% of Private Advisory Group LLC’s holdings, making the stock its 22nd largest position. Private Advisory Group LLC’s holdings in Eli Lilly and Company were worth $18,446,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of LLY. Coastal Bridge Advisors LLC purchased a new stake in shares of Eli Lilly and Company in the 2nd quarter valued at about $2,959,000. Birinyi Associates Inc. grew its position in Eli Lilly and Company by 32.6% in the 3rd quarter. Birinyi Associates Inc. now owns 1,460 shares of the company’s stock valued at $1,689,000 after buying an additional 359 shares during the last quarter. Mosaic Family Wealth Partners LLC boosted its holdings in shares of Eli Lilly and Company by 70.6% in the second quarter. Mosaic Family Wealth Partners LLC now owns 3,455 shares of the company’s stock valued at $4,144,000 after acquiring an additional 1,430 shares in the last quarter. Canton Hathaway LLC lifted its position in Eli Lilly and Company by 160.4% in the third quarter. Canton Hathaway LLC now owns 2,273 shares of the company’s stock valued at $2,630,000 after purchasing an additional 1,400 shares during the period. Finally, Heritage Investors Management Corp boosted its holdings in Eli Lilly and Company by 6.5% in the 3rd quarter. Heritage Investors Management Corp now owns 11,774 shares of the company’s stock valued at $13,624,000 after purchasing an additional 718 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Trading Down 0.3%

Shares of LLY stock opened at $1,433.34 on Friday. The stock has a market cap of $1.35 trillion, a P/E ratio of 46.52, a P/E/G ratio of 1.72 and a beta of 0.40. The company has a quick ratio of 1.00, a current ratio of 1.39 and a debt-to-equity ratio of 1.17. Eli Lilly and Company has a fifty-two week low of $850.51 and a fifty-two week high of $1,460.00. The business has a fifty day simple moving average of $1,236.58 and a 200-day simple moving average of $1,108.27.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, October 29th. The company reported $7.48 EPS for the quarter, topping the consensus estimate of $5.71 by $1.77. The business had revenue of $24.40 billion for the quarter, compared to analyst estimates of $22.58 billion. Eli Lilly and Company had a net margin of 31.90% and a return on equity of 86.76%. The business’s revenue for the quarter was up 38.6% compared to the same quarter last year. During the same period in the previous year, the firm earned $7.02 EPS. On average, analysts forecast that Eli Lilly and Company will post 35.70 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 10th. Shareholders of record on Friday, November 13th will be given a dividend of $1.73 per share. The ex-dividend date is Friday, November 13th. This represents a $6.92 dividend on an annualized basis and a yield of 0.5%. Eli Lilly and Company’s payout ratio is presently 22.46%.

More Eli Lilly and Company News

These are some of the LLY news items that stood out recently:

• Positive Sentiment: China approved orforglipron, making Lilly the first company with an approved GLP-1 weight-loss pill in the country. The approval gives LLY a route into a large obesity-treatment market and a potential edge while rival oral treatments await regulatory decisions. Reuters article
• Positive Sentiment: Lilly broke ground on a $3.5 billion Pennsylvania facility to make injectable medicines, including next-generation candidate retatrutide. The investment could expand manufacturing capacity for future demand and is expected to create 850 permanent jobs, though the benefits will take time to materialize. Lilly facility announcement
• Positive Sentiment: New trial coverage points to broader potential for Lilly’s GLP-1 medicines: orforglipron reportedly showed promise for osteoarthritic knee pain, and Foundayo data indicated improvement in sleep apnea. These possible benefits could expand the drugs’ addressable markets, but further development and evidence remain important. Trial results coverage

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the company. TD Cowen reaffirmed a “buy” rating and set a $1,250.00 price objective on shares of Eli Lilly and Company in a report on Tuesday, September 22nd. Cantor Fitzgerald increased their price target on shares of Eli Lilly and Company from $1,440.00 to $1,600.00 and gave the company an “overweight” rating in a report on Monday, November 2nd. Wall Street Zen upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Saturday, October 31st. Truist Financial reaffirmed a “buy” rating and issued a $1,612.00 target price (up from $1,376.00) on shares of Eli Lilly and Company in a report on Friday, October 30th. Finally, The Goldman Sachs Group reiterated a “buy” rating and set a $1,413.00 price target on shares of Eli Lilly and Company in a research report on Tuesday, October 20th. One analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $1,416.64.

Insider Activity

In other Eli Lilly and Company news, EVP Anat Hakim sold 5,000 shares of the company’s stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $1,402.52, for a total value of $7,012,600.00. Following the sale, the executive vice president owned 4,137 shares of the company’s stock, valued at $5,802,225.24. This represents a 54.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the completion of the sale, the executive vice president owned 54,147 shares in the company, valued at $63,628,139.70. This represents a 10.72% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.14% of the stock is owned by corporate insiders.

Eli Lilly and Company Company Profile

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.